This trial is evaluating whether Aerobic Exercise Therapy will improve 1 primary outcome in patients with COVID-19. Measurement will happen over the course of 30 weeks.
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. Aerobic Exercise Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Although the exact cause of covid-19 is unknown, the overall risk seems to be increased in the presence of certain underlying diseases when assessed at the community level. While the risk is increased in the presence of certain underlying diseases, the effects seem different from the risks associated with certain underlying diseases in isolation, so risk remains unclear. Furthermore, the number and severity of underlying conditions that predispose patients to a particular condition vary from setting to setting. At the individual level, patients with certain conditions tend to be more susceptible to developing severe symptoms of the infection.
Generally, fever is a common symptom of the general population with mild or no clinical symptoms. In more extreme cases, the disease can progress to severe respiratory complications, such as pneumonia, with a case fatality rate of 1% to 10%. Other rare presentations include neurological and cardiac dysfunction with a rate of 20%. Patients who have been infected by these severe variants usually do not seek medical attention, but instead may remain asymptomatic with high-resolution computed tomography scans showing nonspecific findings such as pulmonary opacities, pleural effusion, and/or a pleuritic effusion.
The current outbreak of the coronavirus SARS-CoV-2 can be curable, and has been curable by the standard treatment (i.e. by intensive care unit care combined with antiviral drugs) for the past SARS-CoV-2 outbreak since last decade. The efficacy of the antiviral treatment awaits to be confirmed by a large trials. Results from a recent paper can be helpful to the research institutes to develop an effective drug.
On the basis of the current evidence to date, the World Health Organization (WHO) issued a Phase 4 situation update on February 12, 2020, stating that the risk of death from SARS-CoV2 is comparable to that of SARS and that the virus is very similar to MERS-CoV. The full extent of the spread of SARS-CoV2 remains uncertain. There is a risk of further spread to other countries. It was confirmed that the risk of transmission between humans is high – in certain communities – but that it is lower than the risk of transmission from an infected person to others. There is a high probability that human-to-human transmission will occur.
There is no direct cure for influenza due to the diversity of strains. No medication is a miracle cure for any viral infection and therefore treatment is symptomatic and supportive. While the disease must be supported with medications that decrease the time course, viral shedding, and the number of viral receptors on the respiratory cells in order to prevent complications and infection and restore general health.
Currently, the US is experiencing a relatively low number of cases of covid-19. The National Institutes of Health is planning a surveillance system for disease management and prevention on a national level. While this is critical to the country's ability to prevent the spread of the disease, there is a need to continue the development and refinement and implementation.
Findings from a recent study of this study provide evidence of the benefits of aerobic exercise therapy. These benefits are evident in terms of reduced pain and stiffness intensity in both people in the treatment group who underwent the exercise intervention and those in the control group who did not. This indicates that the exercise intervention is useful for treating acute musculoskeletal conditions and, therefore, this should be implemented in post-exercise support facilities at all institutions.
Aerobic exercise has an emerging and very powerful role in the treatment of neurological diseases and, in particular, in the treatment of different kinds of movement disorders and cognitive disabilities. The therapeutic effects of aerobic exercise are related to a reduction of stress hormones levels, to the induction of neuroprotective factors (such as NGF and BDNF), to neurotransmitter release, inhibition of the monoamine oxidase activity and inhibition of the inflammatory response. Results from a recent clinical trial of a Cochrane systematic review showed that aerobic exercise of moderately intensities, of 2 to 3 hours duration, twice a week for the treatment of peripheral neuropathy in people with diabetes mellitus, is efficacious for the treatment of both sensory and motor peripheral neuropathy of a first or second degree.
Heritability estimates were higher for CTSD in the second sample, possibly owing to smaller effect sizes. In the first sample, the CTSD has a low heritability with a low prevalence rate of comorbid CTSD. We found small but consistent associations between CTSD and CVD, which are consistent with previous findings. Further studies are needed to understand the role of CTSD in the etiology of CVD exacerbation during the infection by coronaviruses.
The average age someone first contacts with symptoms of coronavirus infection is 49 (range 45-52) years. However, this mean age underestimates the true age distribution of coronavirus infection, as some infections manifest with a much lower average age of 40 (range 21-59) years. Therefore, we emphasize the need to report precise age of infection as well as total days infected in laboratory settings such as the WHO.
We found no significant changes in HRQoL in the exercise-guided groups. Even though in the short term exercise may not have an overall beneficial effect on people with advanced COPD.
On the internet we found some evidences that there were possible ways of treating or preventing covid-19 infection; the two most common are: Antigenic, Immunotherapic, or Antibiotic therapy and Noninvasive treatments through nutrition, such as Vitamins or herbal diet or Oasis of Hydration. There were others evidences with no certain proofs or evidences to support the efficacy of the aforementioned therapy. The treatments recommended in the internet should be only regarded as an experimental protocol and should be used only as a last resort. There is a great need for further research in this area.